| D15 | Community-based ART refilling centers as a strategy to prevent LFUs: learnings from the Care and Support Centres (CSC) in India | E-poster | Retention in HIV services |
| D99 | Community- versus individual-level risk compensation with HIV preexposure prophylaxis among men who have sex with men | E-poster | Risk compensation: conceptualisation, assessment, and mitigation |
| D66 | Community led convergence model to prevent vertical transmission of HIV: results from Global Fund supported Ahana project in 14 states of India | E-poster | Sexual and reproductive health, fertility, family planning, pregnancy, and abortion |
| D57 | Community engagement and research on violence and mental health among female sex workers in Nairobi, Kenya: lessons learned from the Maisha Fiti study | E-poster | Community engagement in research and research dissemination |
| D108 | Combined interventions to accelerate delivery on outcomes for young children affected by HIV in southern Africa | Oral abstract session with live Q&A | Safe housing, social protection and other care and support for people affected by HIV |
| A20 | Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremia | Oral abstract session with live Q&A | Eliminating and silencing latency |
| B9 | Combination of Xpert® MTB/RIF and DetermineTM TB LAM assay improves the diagnosis of extrapulmonary tuberculosis at Jimma University Medical Center, Southwest Ethiopia | E-poster | Diagnosis of co-infections and co-morbidities |
| B25 | Combination of high liver and visceral fat predicts diabetes in people living with HIV | E-poster | Hepatic complications (including NASH) |
| C35 | Combination HIV/HCV/HBV/STIs prevention among MSM and use of mobile applications/social networks at the COVID-19 conditions in Ukraine | On-demand oral abstract session | HIV prevention adaptations during COVID-19 |
| B35 | Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/F/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N/R mutation | E-poster | Regimen simplification and switch studies |